Veristat

We’re excited to attend the World Orphan Drug Conference this year! 🔬 Our Chief Commercial Officer, Rachel Page, is ready to dive into key discussions with industry experts, addressing: ➡️ Regulatory changes ➡️ Funding mechanisms ➡️ Drug development ➡️ Patient-centric models ➡️ Innovative trial solutions These conversations are vital for advancing the orphan drug space. We can’t wait to connect with thought leaders, our clients, colleagues, and collaborators in this niche area. Watch the video below to hear more from Rachel and what she’s looking forward to at the event 👇 #WODC2024 #RareDisease #OrphanDrugs #HealthcareInnovation #Veristat #ClinicalResearch

We’re thrilled to be heading to Barcelona soon for the SCOPE Summit for Clinical Ops Executives! Make sure to visit Veristat at Booth #8, where we’ll be showcasing how we can streamline your clinical trials and regulatory submissions. Our experts will be on hand to share insights on how our adaptable, team-based approach empowers sponsors to tackle their toughest challenges—especially in the rare and ultra-rare disease space. Maximize your time by scheduling a meet and greet with AJ Mills, Veristat's VP, Global Commercial, and his team. They’re eager to understand your specific needs and explore how we can support your success. 📅 29-30 October 2024 Looking forward to seeing you there! https://lnkd.in/g5QvE7KN #SCOPEEurope #VeristatInsights #ClinicalExcellence #RareDiseases

Learn how Veristat’s successful track record as a leading rare disease CRO can accelerate your next study. Benefit from our experience with over 350 rare disease clinical trials and nearly 40 marketing applications successfully completed in the last five years alone. Meet with our experts at WODC Booth #35 and have your questions answered. Mark your calendar and attend our Plenary Presentation on “Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective” on Thursday 24th October, 12 pm CET. See you in Barcelona! https://lnkd.in/gmJv4Zbu #WODCEurope #RareDiseases #SJD

It’s almost time! Join Veristat, ADC Therapeutics, Supply Chain Operations, and PrimeTax at the Product Launch Readiness event on October 24 in Lausanne. Discover valuable insights on how Zynlonta™ was successfully launched in Europe and how cross-functional teamwork, careful planning, and the right partners made it all possible. Whether you’re in clinical development or preparing for your next big launch, this is your chance to gain practical insights from industry experts. There are still a few spots left – register now! https://lnkd.in/gBtDQm3Y #LifeSciences #ProductLaunchSuccess #VeristatEvents

Throwback Thursday: Reflecting on Our Growth 🚀 In 2016, we made a significant leap in expanding our global footprint by acquiring Spero Oncology and launching our Strategic Consulting Group. This growth has strengthened our oncology expertise and consulting services, enabling us to help clients navigate complex clinical trials more effectively and drive greater innovation in the fight against cancer. 📈 Discover how our Strategic Consulting service can support your trial's success today: https://lnkd.in/d6zFNfB7 #ThrowbackThursday #VeristatMilestones #ClinicalResearch #CRO #OncologyExcellence

💉 As flu season arrives, vaccines play a crucial role in protecting public health—especially when developed through rigorous clinical trials. 🧪 But vaccines go beyond just the flu. At Veristat, we’ve supported the development of life-saving vaccines, from infectious diseases like COVID-19 to cancer vaccines. With over 175+ vaccine trials and consulting projects, our expertise helps bring vaccines to market safely and quickly. Whether it’s navigating regulatory challenges or ensuring rapid patient recruitment, we’re here to ensure vaccines reach those who need them most. Want to know more about our role in vaccine development? Let’s talk 👉 https://hubs.li/Q02S3kwR0 #FluSeason #Vaccines #ClinicalTrials #PublicHealth #Veristat

Don't miss our plenary presentation at the World Orphan Drug Congress Europe in Barcelona👇💡    Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective    📆 October 24, 2024  🕛12:10 pm CET   Meet scientific experts Rachel Paiva Petean Abu Taleb, Medical Monitor, Veristat, together with Joana Claverol, Clinical Research Director, at Sant Joan de Déu Research Foundation. This session will delve into the complexities of patient recruitment in rare pediatric populations from both a CRO perspective as well as a world leading pediatric clinical site.    👋 See you in Barcelona! https://lnkd.in/gmJv4Zbu   #Veristat #PatientRecruitment #WODC2024 #RareDiseases

The IMDRF released an overview of the implementation status of all International Medical Device Regulators Forum (IMDRF) technical documents up until 30 August 2024. The document reflects IMDRF's mission of strategically accelerating international medical device regulatory convergence to promote an efficient and effective regulatory model for medical devices. 🔭 💡 The overview is organized by levels of implementation and by medical device regulators. Download the final document: https://hubs.li/Q02S3MKR0

When treating diseases in children—especially rare or ultra-rare conditions with limited patient populations and no alternative treatments—getting it right from the start is vital. At Veristat, we’re committed to advancing pediatric health by offering: 🧠 Strategic advice from our scientific experts to plan successful pediatric clinical development programs 🏥 Operational support to find and treat the right patients, ensuring your clinical trial moves forward to its next milestone This National Child Health Day, we reaffirm our dedication to supporting pediatric trials and making a difference in the lives of children facing rare diseases. Learn more: https://hubs.li/Q02S3hrH0 #ChildHealthDay #PediatricResearch #RareDiseases #ClinicalTrials #Veristat

The European Medicines Agency agency issued a set of guiding principles and recommendations for the use of large language models (LLMs) by regulatory agencies in the context of the EU’s artificial intelligence (AI) workplan. Recommendations include: 👉 Ensuring the safe input of data 👉 Applying critical thinking and cross-checking outputs 👉 Keeping up to date with how to make best use of LLMs 👉 Knowing who to consult and report incidents to 🔎 Recommendations https://hubs.li/Q02S3k640 🔎 Guiding principles https://hubs.li/Q02S3jrg0